Politics and drugs

There are two topics in this issue that, in large part, have broad political (as opposed to economic or philosophical) underpinnings, and interestingly, it’s hard to put them on the usual left/right, Democratic/Republican spectrum. The two are medical marijuana and […]

Read More

Partnering to diversify yields rapid growth

Mission Pharmacal Co. (San Antonio, TX), a nearly 70-year-old, family-owned, branded pharmaceutical and consumer goods company has expanded rapidly, showing significant and substantial growth and diversification over the past few years. This success is largely due to a unique, innovative […]

Read More

Drug pricing debate is sharpening

The continuing saga of Gilead Sciences’ Sovaldi and Harvoni drugs, for treating hepatitis C, together with the more recently approved drugs like AbbVie’s Viekira Pak (and more to come), keeps creating ripples that wash through many debates about the US […]

Read More

The Price of Global Health

(Excerpted from ‘The Price of Global Health, 2nd edition, by Ed Schoonveld, Gower Publishing, Burlington, VT)   Market access is the new buzzword in the pharmaceutical industry. Companies re-focus, restructure and add staff to their organizations to better address today’s […]

Read More

A brightening outlook for pharma

I’ve always disliked the phrases “inflection point” or “turning point” because, most of the time, the claim doesn’t stand up to close analysis—a trend that gets recognized as being a clear change has usually been under way for a considerable […]

Read More

Legal uncertainties in the DSCSA

The US Food and Drug Administration (FDA) faces a challenging schedule for implementing the Drug Supply Chain Security Act (DSCSA), enacted on Nov 27, 2013. The DSCSA revamps the requirements for securing prescription drugs throughout the supply chain, and mandates […]

Read More